Alkem Laboratories Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹3,737Cr
- +10.8% YoY
- Net profit
- ₹653Cr
- +1.9% YoY
- Margin
- 22%
- −1 pp YoY
Guidance rank: #61 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Alkem Laboratories Ltd Q3 FY26 key numbers
- Revenue
- Growth drivers include newer products awaiting regulatory approvals (e.g., PFO in the US with high ASP of $9,500), geographic expansion into emerging markets, and deeper market penetration where current presence is low.
As stated in Alkem Laboratories Ltd's Q3 FY26 earnings call transcript · published 7 Aug 2026. Reported figures, not investment advice.
The short version
Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. Alkem anticipates growing its MedTech segment revenues to around INR 1,000 crores in 3-5 years with EBITDA margins improving to 20-25%.
From Alkem Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. (Page 13)
- Growth drivers include newer products awaiting regulatory approvals (e.g., PFO in the US with high ASP of $9,500), geographic expansion into emerging markets, and deeper market penetration where current presence is low. (Pages 12-13)
- MedTech business revenue expected to reach around INR 1,000 crores in 3-5 years with EBITDA margin improving towards 20-25%. (Page 5)
2 more points from Alkem Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Initial investment of around INR 1,100 crores planned for Occlutech acquisition.
- Additional INR 100-200 crores earmarked over 2 years to accelerate R&D programs, including new product launches like LA in Europe.
- MedTech incremental investment expected at INR 200-300 crores over the next 3-4 years, with most significant investment already done.
- Plans to invest further in launching new products (e.g., PFO launch in the U.S. by June 2027) with most R&D spend already completed.
- Refinancing of high-interest debt for Occlutech planned to reduce interest cost from 10% to 5-6%.
2 more points from Alkem Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Alkem Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Alkem Laboratories Ltd — Quarterly revenue & net profit
Alkem Laboratories Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,737 | 3,374 | +10.8% | 4,001 | -6.6% |
| Operating profit (EBITDA) | 828 | 759 | +9.1% | 921 | -10.1% |
| Operating margin | 22% | 23% | -1 pp | 23% | -1 pp |
| Profit before tax | 781 | 731 | +6.8% | 896 | -12.8% |
| Net profit (PAT) | 653 | 641 | +1.9% | 779 | -16.2% |
| EPS (₹) | 53.19 | 52.34 | +1.6% | 63.99 | -16.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹3.7K Cr, net profit ₹521 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Lab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alkem Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alkem Laboratories Ltd Q3 FY26 results?
Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. Alkem anticipates growing its MedTech segment revenues to around INR 1,000 crores in 3-5 years with EBITDA margins improving to 20-25%.
What is Alkem Laboratories Ltd share price analysis?
Alkem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 27.9 with a market cap of ₹68,110 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Laboratories Ltd planning capital expenditure?
Initial investment of around INR 1,100 crores planned for Occlutech acquisition. - Additional INR 100-200 crores earmarked over 2 years to accelerate R&D programs, including new product launches like LA in Europe. - MedTech incremental investment expected at INR 200-300 crores over the next 3-4 years, with most significant investment already done. - Plans to invest further in launching new products (e.g., PFO launch in the U.S.
Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.